. 2020 Jun 21;86(11):2123–2132. doi: 10.1111/bcp.14395

TABLE 1.

Para‐aminosalicylic acid pharmacokinetics

Study	PAS formulation	Route of administration	Dose/dosing frequency	C_max (μg/mL)	AUC (h*μg/mL)	T_max (h)	Half‐life (h)
Hollander 1955 ⁴⁶	PAS‐resin complex	Oral	8 g thrice daily	78–85
Hollander 1955 ⁴⁶	PAS‐resin complex	Oral	16 g^#	180
Riska 1959 ⁶¹	NaPAS granules	Oral	19 g once daily	277
Riska 1959 ⁶¹	NaPAS granules	Oral	22 g once daily	284
Riska 1959 ⁶¹	NaPAS granules	Intravenous	24 g once daily	323
Riska 1962 ⁴³	NaPAS granules	Oral	16‐g single‐dose	240
Riska 1962 ⁴³	NaPAS granules	Oral	4 g 4 times daily	60–80
Riska 1962 ⁴³	PAS (free acid)	Intravenous	16‐g single‐dose over 1 h infusion	450
Riska 1962 ⁴³	PAS (free acid)	Intravenous	16‐g single‐dose over 2 h infusion	350
Riska 1962 ⁴³	PAS (free acid)	Intravenous	16‐g single‐dose over 3 h infusion	290
Yue and Cohen 1966 ⁴⁷	Neopasalate	Oral	6 g once daily	108.9		2
Yue and Cohen 1966 ⁴⁷	NaPAS	Oral	6 g once daily	136.2		2
Yue and Cohen 1966 ⁴⁷	Neopasalate	Oral	12 g once daily	169.8		2
Yue and Cohen 1966 ⁴⁷	NaPAS	Oral	12 g once daily	153.3		2
Wan et al. 1974 ⁴⁴	PAS acid	Oral	4‐g single‐dose	50	209	3.54	0.94
Wan et al. 1974 ⁴⁴	NaPAS	Oral	4‐g single‐dose	155	313	0.83	0.91
Wan et al. 1974 ⁴⁴	CaPAS	Oral	4‐g single‐dose	140	327	1.02	0.91
Wan et al. 1974 ⁴⁴	KPAS	Oral	4‐g single‐dose	121	313	1.1	0.96
Peloquin et al. 1994 ¹⁸	PASER	Oral	4‐g single‐dose	20.23 (8.8) ^a	107.92 (52.45) ^a ^, ^b	7.95 (6.12) ^a	1.62 (0.85) ^a
Peloquin et al. 2001 ⁴¹	PASER	Oral, fasting	6‐g single‐dose	21.4 (11.4–79.3) ^c	140 (20.8–255) ^b ^, ^c	4.43 (2.09–6.64) ^c	1.88 (1.21–3.91) ^c
Peloquin et al. 2001 ⁴¹	PASER	Oral, food	6‐g single‐dose	32.5 (6.83–72.3)c	240 (71.1–472) ^b ^, ^c	6.56 (3.57–8.97) ^c	1.85 (1.10–6.0) ^c
Peloquin et al. 2001 ⁴¹	PASER	Oral, orange juice	6‐g single‐dose	24.7 (6.93–36.4) ^c	175 (29.2–295) ^b ^, ^c	4.57 (3.43–11.1) ^c	2.53 (0.95–4.09) ^c
Peloquin et al. 2001 ⁴¹	PASER	Oral, antacids	6‐g single‐dose	18.4 (5.22–46.0) ^c	124 (55.9–227) ^b ^, ^c	5.25 (2.7–13.0) ^c	2.1 (0.94–3.39) ^c
Liwa et al. 2013 ⁴⁰	PASER	Oral, acidic food or beverage	4 g twice daily	51.3 (20.0) ^a	368 (194.0) ^a ^, ^d	5.2 (2.04)^a
Sy et al. 2015 ²³	PASER	Oral, acidic food or beverage	4 g twice daily	61 (10–112) ^c	428 (119–934) ^c ^, ^d	4.0 (0.0–12.0)^c
Sy et al. 2015 ²³	PASER	Oral, acidic food or beverage	8 g once daily	80 (21–135) ^c	652 (161–1055)^c,d	8 (3.0–121.1)c

All pharmacokinetics parameter values are given as mean unless otherwise stated. Para‐aminosalicylic acid (PAS), sodium PAS (NaPAS), calcium PAS (CaPAS), potassium PAS (KPAS), para‐aminosalicylic acid buffer complex (Neopasalate), granular slow‐release PAS formulation (PASER), peak plasma concentration (C_max), time to C_max (T_max)

^{^a}

mean (standard deviation).

^{^b}

area under the curve from time zero to infinity.

^{^c}

median (range).

^{^d}

area under the curve from 0 to 12 hours.

^{^#}

Dosing frequency is unclear.